Drug Trial Radar · NCT05997576
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
675
Actual
Start
Nov 22, 2023
Primary completion
Feb 17, 2025
Study completion Mar 3, 2025
Sponsor
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for weight management in non-diabetic patients with BMI greater than or equal to 28 kg/m2 or greater than 24 kg/m2 in the presence of comorbidities, in addition to lifestyle intervention (calorie restrict diet and increased physical activity).
Conditions
- Overweight or Obesity
Interventions
TG103 22.5 mgDrug
Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
PlaceboDrug
Subcutaneous injections with calorie restrict diet and increased physical activity for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with weight loss of ≥ 5% at week 40Time frame: From baseline to week 40
- Relative percentage change from baseline in body weight at week 40Time frame: From baseline to week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials Information Group
Shijiazhuang, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.